Genelex receives Innovative Technology Designation from Vizient, Inc. for YouScript®

Designation recognizes the development of new solutions that benefit the health care industry Seattle, WA; January 27, 2015 – Genelex announced its YouScript® Precision Prescribing analytics software has received Innovative Technology designation from Vizient, Inc., formerly Novation, the largest member-owned health care company in the country. The designation was based on reviews of YouScript by hospital experts who attended Vizient’s … Read More

Patricia’s Story

“As both a Mental Health Therapist and a patient, I really believe drug sensitivity testing should be done for everyone. “ My name is Patricia.  In 2005 I was diagnosed with breast cancer and had a right mastectomy.  After undergoing a successful surgery, I began experiencing an unfamiliar feeling.  Immediately after the surgery, I was in intense pain.  Shortly after … Read More

What to Watch for When Taking Dietary or Herbal Supplements

Have you ever taken a vitamin, herbal product or supplement? You’re not alone. In fact, an estimated one-quarter, up to one-half, of adults taking prescription medications also take dietary supplements according to an article by Mayo Clinic Staff. Have you ever wondered if there are any safety concerns with taking one of these products? Most people assume that vitamins and … Read More

A Mother’s Story: Avoiding My Baby’s Potential Overdose

“…the possibility he could have suffered a horrible consequence is very real.” –Sarah Zeller Full disclosure: I am currently employed by Genelex Corporation and have been since 2011. However, I am writing this piece first and foremost as a patient and as a mother. In 2012, I was pregnant with my first child. I had not completed the pharmacogenetic testing … Read More

Tamoxifen and CYP2D6 Interactions

CYP2D6 gene testing for personalizing tamoxifen therapy has been a source of confusion and debate for over a decade. In addition to conflicting outcomes data on breast cancer recurrence rates in women with deficient CYP2D6 enzyme activity (i.e., CYP2D6 Intermediate and Poor Metabolizers) treated with tamoxifen, significant controversy exists around the methodology for using tumor cell DNA to estimate the … Read More